AbbVie (ABBV) announced that a new 6-month 45mg Lupron Depot strength has received Health Canada approval for the treatment of advanced prostate cancer. Lupron Depot is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month). Lupron Depot was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Canada.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: